Asenapine transdermal therapeutic system(Hisamitsu Pharma)

阿塞那平透皮贴剂（久光制药）

Report date: 2025/09/12 16:58:52

Base Information

Drug NameAsenapine transdermal therapeutic system(Hisamitsu Pharma)
Drug Alias NameAsenapinum马来酸氯氧平ASE TTS阿塞纳平阿塞那平 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsBipolar I DisorderSchizophrenia
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited StatesMainland China
Original Approved Date2019/10/11
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHisamitsu Pharmaceutical Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesLian Hong Kong LtdHisamitsu Pharmaceutical Co Inc
Inactive CompaniesN/A
Active IndicationsBipolar I DisorderSchizophrenia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG